☆ 4.6 Article

Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma

NEURO-ONCOLOGY (2017)

Journal

NEURO-ONCOLOGY

Volume 19, Issue 4, Pages 469-474

Publisher

OXFORD UNIV PRESS INC

DOI: 10.1093/neuonc/nox030

Keywords

clinical trials; newly diagnosed glioblastoma; phase II; randomized; single; arm

Categories

Oncology Clinical Neurology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Targeted therapies in patients with newly diagnosed glioblastoma-A systematic meta-analysis of randomized clinical trials

Angelika Scherm, Franziska Maria Ippen, Peter Hau, Hansjoerg Baurecht, Wolfgang Wick, Jens Gempt, Helge Knuettel, Michael F. Leitzmann, Corinna Seliger

Summary: Glioblastoma is the most common malignant brain tumor in adults, and current standard treatment involves surgery followed by radiochemotherapy. This meta-analysis examined the efficacy of targeted therapies in newly diagnosed glioblastoma patients. The analysis showed that targeted agents did not significantly improve overall survival, but they did provide a benefit in progression-free survival, particularly in patients with an unmethylated MGMT promoter. Inhibition of VEGF with bevacizumab was the most effective in prolonging progression-free survival.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial

Andrew B. Lassman, Stephanie L. Pugh, Tony J. C. Wang, Kenneth Aldape, Hui K. Gan, Matthias Preusser, Michael A. Vogelbaum, Erik P. Sulman, Minhee Won, Peixin Zhang, Golnaz Moazami, Marian S. Macsai, Mark R. Gilbert, Earle E. Bain, Vincent Blot, Peter J. Ansell, Suvajit Samanta, Madan G. Kundu, Terri S. Armstrong, Jeffrey S. Wefel, Clemens Seidel, Filip Y. de Vos, Sigmund Hsu, Andres F. Cardona, Giuseppe Lombardi, Dmitry Bentsion, Richard A. Peterson, Craig Gedye, Veronique Bourg, Antje Wick, Walter J. Curran, Minesh P. Mehta

Summary: The use of depatux-m in newly diagnosed glioblastomas (GBMs) with epidermal growth factor receptor gene amplification (EGFR-amp) did not improve overall survival (OS), but showed a longer progression-free survival. There were safety risks associated with the treatment, leading to treatment discontinuation for some patients.

NEURO-ONCOLOGY (2023)

Add to Collection

Article Oncology

Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma

David W. Andrews, Kevin D. Judy, Charles B. Scott, Samantha Garcia, Larry A. Harshyne, Lawrence Kenyon, Kiran Talekar, Adam Flanders, Kofi-Buaku Atsina, Lyndon Kim, Nina Martinez, Wenyin Shi, Maria Werner-Wasik, Haisong Liu, Mikhail Prosniak, Mark Curtis, Rhonda Kean, Donald Y. Ye, Emily Bongiorno, Sami Sauma, Mark A. Exley, Kara Pigott, D. Craig Hooper

Summary: IGV-001 demonstrated good tolerability in newly diagnosed glioblastoma patients, with a significantly improved median progression-free survival (PFS) compared to standard of care (SOC). In patients eligible for Stupp criteria, IGV-001 showed positive outcomes in terms of PFS and overall survival, suggesting a potential immune-mediated mechanism.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Statistics & Probability

Stopping for efficacy in single-arm phase II clinical trials

Rezoanoor Rahman, M. Iftakhar Alam

Summary: Phase II clinical trials investigate effectiveness of new drugs or treatments against diseases, with two-stage designs being popular for their flexibility and efficiency in stopping trials early if needed. Popular adaptive designs consider alternate response rates and aim to minimize expected sample sizes.

JOURNAL OF APPLIED STATISTICS (2022)

Add to Collection

Review Oncology

A Review of Newly Diagnosed Glioblastoma

Bryan Oronsky, Tony R. Reid, Arnold Oronsky, Navjot Sandhu, Susan J. Knox

Summary: Glioblastoma is an aggressive primary intra-axial brain tumor with poor prognosis, and current treatment involves surgery, radiotherapy, and chemotherapy. This review summarizes the characteristics, current treatment options, and potential future therapeutic prospects for the disease.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study

Jie Chen, Tingting Wang, Wanming Liu, Hui Qiu, Nie Zhang, Xueting Chen, Xin Ding, Longzhen Zhang

Summary: This study suggests that extended adjuvant temozolomide treatment can significantly improve the prognosis of newly diagnosed glioblastoma patients, regardless of p53 mutation status. The effect of this treatment also varies among patients with different MGMT methylation, IDH1 mutation, and Ki67 expression levels.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma

Paul D. Brown, Caroline Chung, Diane D. Liu, Sarah McAvoy, David Grosshans, Karine Al Feghali, Anita Mahajan, Jing Li, Susan L. McGovern, Mary-Fran Mcaleer, Amol J. Ghia, Erik P. Sulman, Marta Penas-Prado, John F. de Groot, Amy B. Heimberger, Jihong Wang, Terri S. Armstrong, Mark R. Gilbert, Nandita Guha-Thakurta, Jeffrey S. Wefel

Summary: The study found that proton radiotherapy (PT) did not delay time to cognitive failure in patients with newly diagnosed gliobiastoma (GBM) compared to intensity-modulated radiotherapy (IMRT), but it reduced toxicity and patient-reported fatigue. PT significantly reduced the radiation dose for almost all structures analyzed. Larger randomized trials are needed to further explore the potential benefits of PT in GBM and cognitive preservation in patients with lower-grade gliomas.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma

Loig Vaugier, Loic Ah-Thiane, Maud Aumont, Emmanuel Jouglar, Mario Campone, Camille Colliard, Ludovic Doucet, Jean-Sebastien Frenel, Carole Gourmelon, Marie Robert, Stephane-Andre Martin, Tanguy Riem, Vincent Roualdes, Loic Campion, Augustin Mervoyer

Summary: The study reviewed elderly patients with GBM referred for 6-week CRT, finding that CRT treatment was feasible for this population, even in the case of post-operative neurological disabilities. Age and neurological disabilities did not necessarily affect patient outcomes.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Oncology

Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress

Yaning Wang, Wanqi Chen, Yixin Shi, Chengrui Yan, Ziren Kong, Yuekun Wang, Yu Wang, Wenbin Ma

Summary: This review provides an overview of the phase III clinical trials and prospective phase II clinical trials of targeted drugs for glioma, highlighting the mechanisms of these drugs and analyzing the deficiencies of these trials.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol

Yun Guan, Mingyuan Pan, Jun Yang, Qiuxia Lu, Liangfu Han, Ying Liu, Jing Li, Huaguang Zhu, Xiu Gong, Guanghai Mei, Xiaoxia Liu, Li Pan, Jiazhong Dai, Yang Wang, Enmin Wang, Xin Wang

Summary: This study aims to evaluate the efficacy and toxicity of the combination of hypofractionated stereotactic radiotherapy (HSRT) and intensity-modulated radiotherapy (IMRT) with temozolomide in GBM patients after surgery, and provide evidence for future randomized controlled trials. The study suggests that this treatment approach can improve the survival rate of patients after surgery, with acceptable toxicity and reduced treatment time.

BMC CANCER (2022)

Add to Collection

Article Oncology

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial

Jun Li, Yanqing Huang, Yue Hou, Yan Gu, Chunhua Song, Zheng Ge

Summary: This study evaluates the efficacy and safety of the combination of Aza and HIA as frontline induction therapy for newly diagnosed AML patients eligible for intensive chemotherapy. The results show high rates of complete remission and relapse-free survival, with no significant adverse events reported.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Oncology

Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis

Aaron C. Tan, Sze Huey Tan, Siqin Zhou, Solange Peters, Giuseppe Curigliano, Daniel S. W. Tan

Summary: This study aims to compare efficacy outcomes between early and late phase clinical trials of targeted therapies in lung cancer. The results suggest that efficacy outcomes from early phase trials may reliably translate to larger randomized trials, especially in oncogene-driven lung cancer.

CANCER TREATMENT REVIEWS (2022)

Add to Collection

Article Oncology

Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study

Motoo Nagane, Koichi Ichimura, Ritsuko Onuki, Daichi Narushima, Mai Honda-Kitahara, Kaishi Satomi, Arata Tomiyama, Yasuhito Arai, Tatsuhiro Shibata, Yoshitaka Narita, Takeo Uzuka, Hideo Nakamura, Mitsutoshi Nakada, Yoshiki Arakawa, Takanori Ohnishi, Akitake Mukasa, Shota Tanaka, Toshihiko Wakabayashi, Tomokazu Aoki, Shigeki Aoki, Soichiro Shibui, Masao Matsutani, Keisuke Ishizawa, Hideaki Yokoo, Hiroyoshi Suzuki, Satoshi Morita, Mamoru Kato, Ryo Nishikawa

Summary: This study evaluated the efficacy and safety of bevacizumab in Japanese patients with newly diagnosed glioblastoma and identified an expression classifier that may predict patient prognosis.

CANCERS (2022)

Add to Collection

Article Oncology

Spectroscopic MRI-Based Biomarkers Predict Survival for Newly Diagnosed Glioblastoma in a Clinical Trial

Anuradha G. Trivedi, Karthik K. Ramesh, Vicki Huang, Eric A. Mellon, Peter B. Barker, Lawrence R. Kleinberg, Brent D. Weinberg, Hui-Kuo G. Shu, Hyunsuk Shim

Summary: Due to the infiltrative nature of glioblastoma, standard MRI techniques are not perfect in delineating radiation-targeted tumor volume. Spectroscopic MRI, by measuring the ratio of choline elevation and N-acetylaspartate reduction, can better determine the extent of the tumor. The volume of post-surgical spectroscopically abnormal tissue is a biomarker of overall and progression-free survival, while the volume of residual contrast enhancement determined by T1-weighted contrast-enhanced MRI is not.

CANCERS (2023)

Add to Collection

Article Oncology

Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)

Anne Laprie, Georges Noel, Leonor Chaltiel, Gilles Truc, Marie-Pierre Sunyach, Marie Charissoux, Nicolas Magne, Pierre Auberdiac, Julian Biau, Soleakhena Ken, Fatima Tensaouti, Jonathan Khalifa, Ingrid Sidibe, Franck-Emmanuel Roux, Laure Vieillevigne, Isabelle Catalaa, Sergio Boetto, Emmanuelle Uro-Coste, Stephane Supiot, Valerie Bernier, Thomas Filleron, Muriel Mounier, Muriel Poublanc, Pascale Olivier, Jean-Pierre Delord, Elizabeth Cohen-Jonathan-Moyal

Summary: MRSI-guided dose escalation in newly diagnosed GBM patients did not improve overall survival (OS).

NEURO-ONCOLOGY (2023)

Add to Collection

Article Clinical Neurology

Subgroup and subtype-specific outcomes in adult medulloblastoma

Hallie Coltin, Lakshmikirupa Sundaresan, Kyle S. Smith, Patryk Skowron, Luca Massimi, Charles G. Eberhart, Karisa C. Schreck, Nalin Gupta, William A. Weiss, Daniela Tirapelli, Carlos Carlotti, Kay K. W. Li, Marina Ryzhova, Andrey Golanov, Olga Zheludkova, Oksana Absalyamova, Konstantin Okonechnikov, Damian Stichel, Andreas von Deimling, Caterina Giannini, Scott Raskin, Erwin G. Van Meir, Jennifer A. Chan, Daniel Fults, Lola B. Chambless, Seung-Ki Kim, Alexandre Vasiljevic, Cecile Faure-Conter, Rajeev Vibhakar, Shin Jung, Sarah Leary, Jaume Mora, Roger E. McLendon, Ian F. Pollack, Peter Hauser, Wieslawa A. Grajkowska, Joshua B. Rubin, Marie-Lise C. van Veelen, Pim J. French, Johan M. Kros, Linda M. Liau, Stefan M. Pfister, Marcel Kool, Noriyuki Kijima, Michael D. Taylor, Roger J. Packer, Paul A. Northcott, Andrey Korshunov, Vijay Ramaswamy

Summary: Medulloblastoma in adults can be classified into WNT, SHH, Group 3, and Group 4 subgroups, with SHH tumors being diagnosed at an older age. The 5-year progression-free survival varies among different subtypes, but clinical variables do not show a significant association with subtype-specific PFS.

ACTA NEUROPATHOLOGICA (2021)

Add to Collection

Article Oncology

Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features

Manabu Natsumeda, Michael Chang, Ramil Gabdulkhaev, Haruhiko Takahashi, Yoshihiro Tsukamoto, Yu Kanemaru, Masayasu Okada, Makoto Oishi, Kouichirou Okamoto, Fausto J. Rodriguez, Akiyoshi Kakita, Yukihiko Fujii, Karisa C. Schreck

Summary: Detecting BRAF V600E mutation in GBMs is crucial due to potential treatment implications, however, the scarcity of these mutations poses challenges for molecular testing in all GBMs. Analyzing clinical, radiographic, and pathologic features of BRAF V600E-mutant GBM compared to controls revealed specific MRI characteristics, higher likelihood of total resection, and distinctive epithelioid features, emphasizing the importance of testing for BRAF V600E in IDH-wildtype GBM.

BRAIN TUMOR PATHOLOGY (2021)

Add to Collection

Article Oncology

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma

Karisa C. Schreck, Andrew Morin, Guisheng Zhao, Amy N. Allen, Patrick Flannery, Michael Glantz, Adam L. Green, Chris Jones, Kenneth L. Jones, Lindsay B. Kilburn, Kellie J. Nazemi, David Samuel, Bridget Sanford, David A. Solomon, Jiawan Wang, Christine A. Pratilas, Theodore Nicolaides, Jean M. Mulcahy Levy

Summary: This study identified various resistance mechanisms to BRAFi in gliomas, suggesting the need for combination therapies. Different resistance mechanisms require specific strategies to overcome, such as restoring wild-type PTEN or combination therapy with MEKi or EGFR inhibitors.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Clinical Neurology

Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma

Karisa C. Schreck, Fang-Chi Hsu, Adam Berrington, Bobbie Henry-Barron, Diane Vizthum, Lindsay Blair, Eric H. Kossoff, Linda Easter, Christopher T. Whitlow, Peter B. Barker, Mackenzie C. Cervenka, Jaishri O. Blakeley, Roy E. Strowd

Summary: The study examined the feasibility and safety of a ketogenic dietary intervention in patients with glioma. Results showed significant systemic and cerebral metabolic changes in participants, with ketonuria being a better indicator of systemic activity than patient-reported food records.

NEUROLOGY (2021)

Add to Collection

Article Oncology

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

Jarushka Naidoo, Karisa C. Schreck, Wei Fu, Chen Hu, Alexander Carvajal-Gonzalez, Roisin M. Connolly, Cesar A. Santa-Maria, Evan J. Lipson, Matthias Holdhoff, Patrick M. Forde, Christopher Douville, Joanne Riemer, Amanda Barnes, Kristin J. Redmond, Lawrence Kleinberg, Brandi Page, Nafi Aygun, Kenneth W. Kinzler, Nickolas Papadopoulos, Chetan Bettegowda, Arun Venkatesan, Julie R. Brahmer, Stuart A. Grossman

Summary: Pembrolizumab showed a 38% CNS response rate in patients with LMM, with a tolerable safety profile and deep responses in selected patients with ICI-responsive tumors. CSF t-DNA may be sensitive for LMM detection, and the immunologic subsets of CNS response require further investigation.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Review Oncology

High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes

Xiaobu Ye, Karisa C. Schreck, Byram H. Ozer, Stuart A. Grossman

Summary: Outcomes for patients with high grade gliomas have remained stagnant for the past thirty years, leading to a need for increased flexibility in the design and conduct of clinical brain tumor trials. Flexible clinical trial designs offer smaller sample sizes, adaptive modifications, fewer control arms, and the inclusion of multiple arms in one study. However, challenges related to identifying active pharmaceutical agents and delivering them to brain tumor tissue in therapeutic concentrations continue to hinder progress in treating high grade gliomas.

EXPERT REVIEW OF ANTICANCER THERAPY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

Patience Odeniyide, Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, Ana Calizo, Lindy Zhang, Fausto J. Rodriguez, John M. Gross, Amy N. Allen, Xiaolin Wan, Romel Somwar, Karisa C. Schreck, Linda Kessler, Jiawan Wang, Christine A. Pratilas

Summary: This study suggests that the FTase inhibitor tipifarnib may be an effective therapeutic strategy for a subset of fusion-negative RMS patients, especially those with HRAS mutations.

ONCOGENE (2022)

Add to Collection

Correction Biochemistry & Molecular Biology

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Apr, 10.1038/s41388-02202305-x, 2022)

Patience Odeniyide, Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, Ana Calizo, Lindy Zhang, Fausto J. Rodriguez, John M. Gross, Amy N. Allen, Xiaolin Wan, Romel Somwar, Karisa C. Schreck, Linda Kessler, Jiawan Wang, Christine A. Pratilas

ONCOGENE (2022)

Add to Collection

Article Oncology

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report

Vasu Munjapara, Thatcher Heumann, Karisa C. Schreck, John M. Gross, Carlos Perez-Heydrich, Sachin K. Gujar, Charles G. Eberhart, Matthias Holdhoff

Summary: Advancements in understanding the biology of GBM and genomic sequencing have led to the discovery of targetable mutations. This case study presents a patient with metastatic GBM who achieved a response to combination BRAF-MEK targeted inhibition.

CASE REPORTS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Integrated molecular and clinical analysis of BRAF-mutant glioma in adults

Karisa C. Schreck, Pinky Langat, Varun M. Bhave, Taibo Li, Eleanor Woodward, Christine A. Pratilas, Charles G. Eberhart, Wenya Linda Bi

Summary: BRAF mutations play a significant role in pediatric low-grade glioma, but their impact on adult glioma remains unclear. In this study, a cohort of over 300 glioma patients, including more than 200 adults, with BRAF mutations was characterized. The results showed that adult and pediatric BRAF-mutant gliomas have distinct clinical and molecular features, and BRAF(V600E) alterations were associated with improved survival in adult glioma. Additionally, BRAF(V600E) alterations in adults conferred sensitivity to targeted therapies.

NPJ PRECISION ONCOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Management and Molecular Characterization of Intraventricular Glioblastoma: A Single-Institution Case Series

Megan Parker, Anita Kalluri, Joshua Materi, Sachin K. Gujar, Karisa Schreck, Debraj Mukherjee, Jon Weingart, Henry Brem, Kristin J. Redmond, Calixto-Hope G. Lucas, Chetan Bettegowda, Jordina Rincon-Torroella

Summary: This article presents a case series of nine patients with intraventricular glioblastoma (IVGBM) and explores the molecular alterations found in these rare tumors. Further studies are needed to understand the genetic landscape and unique pathophysiology of IVGBM compared to parenchymal glioblastoma. Prompt intervention is necessary for the management of IVGBM due to their anatomical location, presentation with obstructive hydrocephalus, and fast growth.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Meeting Abstract Oncology

PRELIMINARY RESULTS OF BINIMETINIB AND ENCORAFENIB IN ADULTS WITH RECURRENT BRAF V600E-MUTATED HIGH-GRADE GLIOMA.

Karisa Schreck, Roy Strowd, L. Burt Nabors, Ben Ellingson, Joy Fisher, Serena Desideri, Neeraja Danda, Michelle Rudek, Stuart Grossman, Xiaobu Ye

NEURO-ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Integrated molecular and clinical analysis of BRAF-mutant glioma in adults

K. Schreck, P. Langat, T. Li, V. Bhave, C. Pratilas, C. Eberhart, W. L. Bi

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Meeting Abstract Clinical Neurology

Molecularly Distinct Low Grade Gliomas in a Single Individual

Bharat Ramlal, Karisa Schreck, Charles Eberhart, David Nauen

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response.

Jarushka Naidoo, Karisa C. Schreck, Chen Hu, Christopher Blair Douville, Cesar Augusto Santa-Maria, Roisin M. Connolly, Matthias Holdhoff, Evan J. Lipson, Rose Parkinson, Joanne Riemer, Amanda Barnes, Arun Venkatesan, Chetan Bettegowda, Stuart A. Grossman, Julie R. Brahmer

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.